Periodontal DiseasesFLOE_longNCT07167771
LONGITUDINAL FOLLOW-UP STUDY TO DETERMINE THE PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED PATIENTS
An observational study of Periodontal Diseases, run by Universidad Complutense de Madrid at 2 sites in Spain.
Trial summary
Objective: The main aim of this longitudinal clinical study is to evaluate the predictive ability of a panel of salivary biomarkers in determining periodontal health status in 2 years follow up in a group of healthy and periodontally affected individuals. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Periodontal Diseases
- How many people
- 100 participants
- Where
- 2 sitesSpain
- Study dates
- 1 Oct 2025to Oct 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: This study will be conducted as a 2y longitudinal, observational follow-up study, from a previous cross-sectional study (code 23/481-E). The study will be conducted at the Faculty of Dentistry University Complutense of Madrid, Spain. The research group and facilities associated with the university will serve as the primary study setting for participant recruitment, data collection, and analysis.
Who may be able to join
- Participants from the cohort involved in the previous cross-sectional study (code 23/481-E).
- Adults (≥ 18-year-old)
- Being able to sign an informed consent form
- Willing to participate in this observational investigation
- Diagnosed as periodontally healthy, gingivitis, treated periodontitis patient (stable / unstable), periodontitis stages I \& II, or periodontitis stages III and IV (Papapanou et al. 2023) in the previous cross-sectional study (code 23/481-E)
Who cannot join
- Patients fitting to all the above inclusion criteria will be excluded from the study if unable to attend to the study-related procedures.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Spain2 sites, 2 recruiting
- Recruiting
Faculty of Dentistry, University Complutense of Madrid (UCM)
Madrid, 28040
Elena Figuero Ruiz, 0034913942186, elfiguer@ucm.es
Mariano Sanz, Prof.
- Recruiting
Faculty of Dentistry, University Complutense of Madrid (UCM)
Madrid, 28040
Elena Figuero, Prof., 0034913942186, elfiguer@ucm.es
Claudia Sola, PhD student
About this study
Objective: The main aim of this longitudinal clinical study is to evaluate the predictive ability of a panel of salivary biomarkers in determining periodontal health status in 2 years follow up in a group of healthy and periodontally affected individuals.
Material and methods: In this longitudinal, observational follow-up study, patients previously enrolled in a cross-sectional study at the Periodontal Postgraduate Clinic, University Complutense of Madrid, will be re-evaluated over a 2-year period. Participants (≥18 years) will be categorized into diagnostic groups based on the 2018 classification of periodontal diseases, including periodontally healthy, gingivitis, treated periodontitis (stable/unstable), and various stages of periodontitis. The study will include follow-up visits at 1 and 2 years. At each visit, participants will undergo a comprehensive medical examination to assess age, gender, weight, height, waist circumference, blood pressure, temperature, smoking and alcohol history, systemic health, and HbA1c levels. A periodontal examination will be performed at six sites per tooth, and clinical parameters including plaque, bleeding on probing, probing depth, recession, and tooth loss will be recorded. Saliva and subgingival plaque samples will be collected for biomarker and microbiological analysis. Salivary biomarkers will be measured using multiplex immunoassays, and bacterial quantification will be performed by multiplex qPCR. Data analyses: Descriptive statistics will be used to report the clinical variables and patients will be grouped according to the pre-established diagnostic categories (periodontally healthy, gingivitis, treated periodontitis patient. In order to determine the possible statistical relationship with the medical, biochemical and microbiological variables assessed, a crude bivariate analysis will first be performed by applying a mean comparison test for quantitative variables (ANOVA) and a proportion comparison test for categorical variables (Chi-square). Subsequently, those variables identified as relevant in the crude analyses will be included as confounding and/or interaction factors in a binary logistic regression model, considering the presence of periodontitis as a response variable, in order to obtain crude and adjusted OR values, together with their corresponding 95% CIs. Based on the results obtained in the biomarker analysis, a relevant statistical analysis will be performed, taking into account all the variables collected in the study. For periodontitis cases, treatment response over time will be analyzed, with subgroup comparisons between responders and non-responders.
- Conditions
- Periodontal Diseases
- Being tested
- No intervention
- Keywords
- periodontal diseases, saliva, biomarkers, prediction, periodontopathogens, interleukin 1, MMP-8
- Medical subject headings
- Periodontal Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No interventionOther
There is not intervention in these patients, appart from their normal dental check-up visits.
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 | Participants involved in an already done cross-sectional study (code 23/481-E). Receives: Other: No intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Salivary biomarkers
Concentrations of specific biomarkers (IL-1 and MMP-8) analyzed using multiplex commercial diagnostic tests.
Measured: Baseline, 1 and 2 years
Secondary outcomes (18)
Age
Participant's age in years.
Measured: Baseline, 1 and 2 years
Gender
Gender
Measured: Baseline, 1 and 2 years
Weight
Weight (kg)
Measured: Baseline, 1 and 2 years
Height
Height (cm)
Measured: Baseline, 1 and 2 years
Waist circumference
A measuring tape will be used, and the determination will be made above the hip bone
Measured: Baseline, 1 and 2 years
HbA1c
Following the instructions from the manufacturer of the device (A1CNow+; Bayer) and diabetic risk questionnaire (Finn-risk)
Measured: Baseline, 1 and 2 years
Blood pressure
The procedure will follow the recommendations in the clinical practice guidelines of the American Heart Association (AHA) {Whelton, 2018 #466}. In summary, a validated and approved blood pressure monitor (Omron M6 COMFORT IT HEM-7322U-E) will be used with the patient seated, back straight, and arms supported at heart level. After the initial measurement, there will be a 5-minute rest period before taking a second reading. The average of the two readings will be considered valid.
Measured: Baseline, 1 and 2 years
Temperature
Participant's body temperature in degrees Celsius.
Measured: Baseline, 1 and 2 years
Drug, alcohol, and smoking history
History of participant's drug, alcohol, and smoking habits.
Measured: Baseline, 1 and 2 years
Nicotine dependency
Assessment of nicotine dependency using the Fagerström Test for Nicotine Dependence.
Measured: Baseline, 1 and 2 years
Health anamnesis
Relevant systemic health information collected through a complete health history questionnaire
Measured: Baseline, 1 and 2 years
Presence and quantification of specific periodontal pathogens
- gingivalis, A. actinomycetemcomitans, T. forsythia detected through real time PCR analysis
Measured: Baseline, 1 and 2 years
Plaque index
categorized as presence/absence
Measured: Baseline, 1 and 2 years
Bleeding on probing
assessed dichotomously within 15 seconds after probing
Measured: Baseline, 1 and 2 years
Suppuration on probing
assessed dichotomously within 15 seconds after probing
Measured: Baseline, 1 and 2 years
Probing depth
defined as the distance in mm between the bottom of the pocket and the gingival margin
Measured: Baseline, 1 and 2 years
Recession
defined as the distance in mm between the amelocemental boundary and the gingival margin. The sum of probing depth and recession will determine the patient's clinical attachment loss
Measured: Baseline, 1 and 2 years
Number of teeth lost and reason
Number of teeth lost and reason
Measured: Baseline, 1 and 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2025
- Study start1 Oct 2025
- Primary completionOct 2027 (estimated)
- Study completionOct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontal DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidad Complutense de Madrid
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07167771
- Sponsor's protocol ID
- 165-290725
- Acronym
- FLOE_long
- Status last verified
- Jun 2026
- First submitted
- 4 Sep 2025
- Last updated
- 29 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- LONGITUDINAL FOLLOW-UP STUDY TO DETERMINE THE PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED PATIENTS
- ClinicalTrials.gov ID
- NCT07167771
- Acronym / sponsor ID
- FLOE_long / 165-290725
- Conditions
- Periodontal Diseases
- Keywords
- periodontal diseases, saliva, biomarkers, prediction, periodontopathogens, interleukin 1, MMP-8
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Universidad Complutense de MadridUniversity, hospital or other
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- Oct 2027 (estimated)
- Study completion
- Oct 2028 (estimated)
- First posted
- 11 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective: The main aim of this longitudinal clinical study is to evaluate the predictive ability of a panel of salivary biomarkers in determining periodontal health status in 2 years follow up in a group of healthy and periodontally affected individuals.
Material and methods: In this longitudinal, observational follow-up study, patients previously enrolled in a cross-sectional study at the Periodontal Postgraduate Clinic, University Complutense of Madrid, will be re-evaluated over a 2-year period. Participants (≥18 years) will be categorized into diagnostic groups based on the 2018 classification of periodontal diseases, including periodontally healthy, gingivitis, treated periodontitis (stable/unstable), and various stages of periodontitis. The study will include follow-up visits at 1 and 2 years. At each visit, participants will undergo a comprehensive medical examination to assess age, gender, weight, height, waist circumference, blood pressure, temperature, smoking and alcohol history, systemic health, and HbA1c levels. A periodontal examination will be performed at six sites per tooth, and clinical parameters including plaque, bleeding on probing, probing depth, recession, and tooth loss will be recorded. Saliva and subgingival plaque samples will be collected for biomarker and microbiological analysis. Salivary biomarkers will be measured using multiplex immunoassays, and bacterial quantification will be performed by multiplex qPCR. Data analyses: Descriptive statistics will be used to report the clinical variables and patients will be grouped according to the pre-established diagnostic categories (periodontally healthy, gingivitis, treated periodontitis patient. In order to determine the possible statistical relationship with the medical, biochemical and microbiological variables assessed, a crude bivariate analysis will first be performed by applying a mean comparison test for quantitative variables (ANOVA) and a proportion comparison test for categorical variables (Chi-square). Subsequently, those variables identified as relevant in the crude analyses will be included as confounding and/or interaction factors in a binary logistic regression model, considering the presence of periodontitis as a response variable, in order to obtain crude and adjusted OR values, together with their corresponding 95% CIs. Based on the results obtained in the biomarker analysis, a relevant statistical analysis will be performed, taking into account all the variables collected in the study. For periodontitis cases, treatment response over time will be analyzed, with subgroup comparisons between responders and non-responders.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cohort 1 | – | Other: No interventionParticipants involved in an already done cross-sectional study (code 23/481-E). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- This study will be conducted as a 2y longitudinal, observational follow-up study, from a previous cross-sectional study (code 23/481-E). The study will be conducted at the Faculty of Dentistry University Complutense of Madrid, Spain. The research group and facilities associated with the university will serve as the primary study setting for participant recruitment, data collection, and analysis.
Key inclusion criteria (5 listed)
- Participants from the cohort involved in the previous cross-sectional study (code 23/481-E).
- Adults (≥ 18-year-old)
- Being able to sign an informed consent form
- Willing to participate in this observational investigation
- Diagnosed as periodontally healthy, gingivitis, treated periodontitis patient (stable / unstable), periodontitis stages I \& II, or periodontitis stages III and IV (Papapanou et al. 2023) in the previous cross-sectional study (code 23/481-E)
Key exclusion criteria (1 listed)
- Patients fitting to all the above inclusion criteria will be excluded from the study if unable to attend to the study-related procedures.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No interventionThere is not intervention in these patients, appart from their normal dental check-up visits. | Other | Cohort 1 |
Primary outcome
Salivary biomarkers
Time frame: Baseline, 1 and 2 years
Concentrations of specific biomarkers (IL-1 and MMP-8) analyzed using multiplex commercial diagnostic tests.
18 secondary outcomes
Age
Time frame: Baseline, 1 and 2 years
Gender
Time frame: Baseline, 1 and 2 years
Weight
Time frame: Baseline, 1 and 2 years
Height
Time frame: Baseline, 1 and 2 years
Waist circumference
Time frame: Baseline, 1 and 2 years
HbA1c
Time frame: Baseline, 1 and 2 years
Blood pressure
Time frame: Baseline, 1 and 2 years
Temperature
Time frame: Baseline, 1 and 2 years
Drug, alcohol, and smoking history
Time frame: Baseline, 1 and 2 years
Nicotine dependency
Time frame: Baseline, 1 and 2 years
Health anamnesis
Time frame: Baseline, 1 and 2 years
Presence and quantification of specific periodontal pathogens
Time frame: Baseline, 1 and 2 years
Plaque index
Time frame: Baseline, 1 and 2 years
Bleeding on probing
Time frame: Baseline, 1 and 2 years
Suppuration on probing
Time frame: Baseline, 1 and 2 years
Probing depth
Time frame: Baseline, 1 and 2 years
Recession
Time frame: Baseline, 1 and 2 years
Number of teeth lost and reason
Time frame: Baseline, 1 and 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Periodontal Diseases
RecruitingObservational study
Effects Of Periodontal Therapy In Patients With Inflammatory Bowel Disease
Periodontal Diseases, IBD
Not yet recruiting
Effect of Customized Versus Stock Healing Abutments on Peri-Implant Soft Tissue
Peri-Implantitis
Not yet recruitingPhase 3
Periodontal Disease and Small Vulnerable Newborns in Rural Nepal: A Community-based Trial
Preterm Birth, Low Birth Weight
Active, not recruitingObservational study
A Retrospective Cohort Study on the Non-Surgical Treatment of Periapical Inflammatory Lesions With Vitapex Paste
Periapical Periodontitis, Periapical Abscess
Not yet recruitingObservational study
Diagnostic Accuracy of Large Language Models for Peri-Implant Marginal Bone Loss on Panoramic Radiographs
Peri-implantitis, Alveolar Bone Loss
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Periodontal Diseases, run by Universidad Complutense de Madrid at 2 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Elena Figuero, Prof. (+34 913942186, elfiguer@ucm.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Salivary biomarkers (time frame: Baseline, 1 and 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.